$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: FL, STRM, TXNM, and CTLP
Foot Locker, Inc. (NYSE: FL), relating to the proposed merger with DICK'S Sporting Goods, Inc. Under the terms of the agreement, Foot Locker shareholders will elect to receive either $24.00 in cash or 0.1168 shares of DICK'S common stock for each share of Foot Locker common stock.
ACT NOW. The Shareholder Vote is scheduled for August 22, 2025.
Click here for more information https://monteverdelaw.com/case/foot-locker-inc/. It is free and there is no cost or obligation to you.
Streamline Health Solutions, Inc. (NASDAQ: STRM) relating to its sale to MDaudit for $5.34 per share.
ACT NOW. The Shareholder Vote is scheduled for August 7, 2025.
Click here for more information https://monteverdelaw.com/case/streamline-health-solutions-inc/. It is free and there is no cost or obligation to you.
TXNM Energy (NYSE: TXNM), relating to the proposed merger with Blackstone Infrastructure. Under the terms of the agreement, Blackstone Infrastructure will acquire TXNM Energy for $61.25 per share in cash.
Click here for more information https://monteverdelaw.com/case/txnm-energy-txnm/. It is free and there is no cost or obligation to you.
Cantaloupe, Inc. (NASDAQ: CTLP) related to its sale to 365 Retail Markets, LLC for $11.20 per share in cash.
Click here for more information https://monteverdelaw.com/case/cantaloupe-inc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court?
When was the last time you recovered money for shareholders?
What cases did you recover money in and how much?
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:Juan Monteverde, Esq.MONTEVERDE & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4740New York, NY 10118United States of Americajmonteverde@monteverdelaw.comTel: (212) 971-1341
Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, July 15, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow, Inc. ('Harrow' or 'the Company') (NASDAQ: HROW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Harrow announced its financial results for Q1 2025 on May 8, 2025. The Company reported revenues that missed consensus estimates and adjusted EBITDA of –$1.9 million. Based on this news, shares of Harrow fell by more than 4%. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335info@
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Faruqi & Faruqi Reminds Hims & Hers Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Novo Nordisk further stated 'the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies' may contain 'unsafe and illicit foreign ingredients.' On this news, Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, thereby injuring investors. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Hims & Hers Health class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Free Malaysia Today
5 hours ago
- Free Malaysia Today
Nasdaq, S&P 500 futures at record peak as bank earnings kick in, CPI on tap
Nasdaq 100 futures also rose 0.58% to record highs, powered by a jump in Nvidia. (Wikimedia Commons pic) NEW YORK : Futures tied to the Nasdaq and the S&P 500 hit record highs today as the second-quarter (Q2) earnings season began and investors awaited upcoming inflation data that could influence the Federal Reserve's (Fed) policy moves. At 6.53am, S&P 500 E-minis were up 22.5 points, or 0.36% to reach an all-time high. Dow E-minis were down 32 points, or 0.07%. Nasdaq 100 futures also rose 0.58% to record highs, powered by a jump in Nvidia after the chip designer announced plans to restart sales of its H20 AI chip to China. The company's shares were up about 5% in premarket trading. The news also lifted other chipmakers, with Advanced Micro Devices rising 4.5%, Marvell Technology up 2.7% and US-listed shares of TSM gaining 2.3%. Wall Street kick-started another earnings season with major financial institutions reporting results. JPMorgan Chase's shares remained steady after the company lifted its net interest income forecast for 2025. Additionally, Wells Fargo's profit rose in Q2 as it set aside less money to shield for potential bad loans. However, its shares slipped 1.1%. Meanwhile, BlackRock's assets under management touched a new high, hitting US$12.53 trillion in Q2 on prospects of trade deals and interest-rate cuts in the US. Its shares were down 0.9%. Despite President Donald Trump's renewed tariff threats – this time aimed at Russia – markets largely brushed off the rhetoric, focusing instead on a breakthrough from negotiations with US trade partners. Hopes were buoyed after Trump signaled willingness to talk, following his weekend warning of 30% tariffs on the EU and Mexico starting Aug 1. Yesterday, all three indexes closed higher, with the Nasdaq finishing at a record high. All eyes are on the June consumer price report, due at 8.30am, that will allow investors to assess how Trump's tariffs have affected price pressures. Economists surveyed by Reuters expect headline inflation accelerated to 2.7% last month on a year-over-year basis, up from 2.4% in May, while core inflation is forecast to tick up to 3% from 2.8%. Elias Haddad, senior markets strategist at Brown Brothers Harriman, noted that the effect of tariffs on inflation has been muted, but stuck to the view that 'higher US levies is a downside risk to US growth and upside risk to inflation'. The odds of a July rate cut have faded, while markets are pricing in a roughly 60% chance of a move in September, according to CME FedWatch. Later in the day, at least four Fed officials, including Board governor Michael Barr, are scheduled to speak, potentially offering fresh clues on the central bank's next steps. Among other movers, Trade Desk surged 14.6% after the software firm was set to join the benchmark S&P 500 index.
